Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), announced that the first patient in China has been dosed in the Phase 1 clinical trial of RB-164™ (SYS6005), a next-generation antibody-drug-conjugate (ADC) targeting ROR-1.

“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert Brooks, JD, Chief Executive Officer of Radiance.

“The preclinical and non-human primate studies suggest RB-164™ has the potential to translate into meaningful clinical benefits with acceptable toxicity for patients with ROR-1 positive hematologic cancers such as Diffuse Large B-Cell Lymphoma and solid tumors,” said Martin Olivo, MD, Chief Medical Officer of Radiance.

The Phase 1 portion of the open label study which will be conducted by Radiance in the U.S., Australia and Europe will evaluate the safety, efficacy and pharmacokinetics (PK) of RB-164™ in participants with hematologic cancers such as lymphoma and advanced solid tumors that are associated with high ROR-1 expression. The Phase 1 clinical trial initiates with dose escalation followed by dose optimization and expansion.